Researchers at MIT and collaborators have pioneered the application of generative artificial intelligence to design novel antibiotic molecules capable of targeting drug-resistant pathogens such as Neisseria gonorrhoeae and MRSA. By computationally generating and screening millions of compounds with novel structures and mechanisms, this approach transcends traditional chemical libraries to explore vast chemical spaces. The breakthrough underscores the potential for AI to accelerate discovery, optimize lead candidates, and address antibiotic resistance challenges in pharmaceutical development.